Transcranial Magnetic Stimulation on Dorsomedial Prefrontal Cortex in Borderline Personality Disorder

Not Applicable

• Conditions: Borderline Personality Disorder
• Interventions: Device: Repetitive Transcranial Magnetic Stimulation

• Registration Number: NCT03832777
• Lead Sponsor: Universidad Autonoma de Queretaro

Brief Summary

This study evaluates the effect of 5Hz repetitive Transcranial Magnetic Stimulation (rTMS) on Dorsomedial Prefrontal Cortex on Borderline Personality Disorder (BPD).

Detailed Description

Borderline Personality Disorder (BPD) is a mental illness with a high worldwide prevalence and economic costs, and is characterized with impulsiveness, both interpersonal relationships and emotional disturbance. Symptoms are related to hypofunction of frontal areas like Dorsomedial Prefrontal Cortex (DMPFC). Psychotherapy is the base treatment in this disease, but economic costs and long-time therapy have made difficult the attachment. Repetitive Transcranial Magnetic Stimulation(rTMS), authorized by Food and Drug Administration (FDA) on Major Depressive Disorder (MDD) treatment has proven good results in previous works in BPD clinical characteristics on both dorsolateral prefrontal cortex (DLPFC) and enhancement in depressive symptoms stimulating DMPFC in high frequency. However, there are no current research that have addressed the use of low-frequency on this anatomical area.

Study Timeline

• Study Start: 2018-03-05
• Status Verified: 2019-01
• Primary Completion: 2019-01-30
• Study First Submitted: 2019-02-05
• Study First Submitted QC: 2019-02-05
• Study First Posted: 2019-02-06
• Last Update Submitted: 2019-02-12
• Last Update Posted: 2019-02-15
• Study Completion: 2019-08-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• 18-45 years old.
• Meet DSM 5 (Diagnostic and Statistical Manual, 5th edition) diagnostic criteria for Borderline Personality Disorder.
• Score of >7 in the Diagnostic Interview for Borderline (Revised version, DIB-R)
• All patients must have follow-up psychotherapy of at least one month.
• No changes on pharmacological treatment within the last month.
• Patients must provide their oral and written informed consent.

Exclusion Criteria

• Subjects with history of traumatic brain injury with loss of consciousness.
• Subjects with intracranial metallic objects or metal plates in the skull.
• Subjects diagnosed with uncontrolled chronic (for example: hypertension, diabetes) or neurological diseases.
• Comorbidity with other mental illness. (Except Depressive symptoms and Anxiety Disorders).
• Presence of psychotic symptoms.
• Alterations in the electroencephalogram (epileptiform activity).
• Self injury or suicidal attempts in less than 2 weeks (depends on the severity and deepness).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo Stimulation	Repetitive Transcranial Magnetic Stimulation	This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 15 sessions, one per weekday.
5 Hz Stimulation	Repetitive Transcranial Magnetic Stimulation	This group will receive 5Hz (Hertz) Dorsomedial Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, once per weekday, with a final result of 15 sessions in this modality.

Primary Outcome Measures

Name	Time	Method
Borderline Symptoms List (BSL)	6 weeks	BSL is a 23 item scale that evaluates the general symptoms and 11 items with behavioural evaluation of BPD.
Global Clinical Impression of BPD (GCI-BPD)	6 weeks	CGI-BPD is a 10 item evaluation that rates the severity of BPD distributed in 9 neuropsychological domains with a final global score.
Borderline Evaluation of Severity Over Time (BEST)	6 weeks	BEST is a 15 item scale that evaluates the severity in this pathology according to 3 areas: thoughts, emotions and typical behaviours.

Secondary Outcome Measures

Name	Time	Method
Hamilton Anxiety Rating Scale (HARS)	6 weeks	HARS is a 14 items rating scale that evaluates the severity of anxiety symptoms in patients.
Barratt Impulsivity Scale (BIS-11)	6 weeks	The Barratt Impulsiveness Scale is a questionnaire designed to assess the personality / behavioral construct of impulsiveness; composed of 30 items describing common impulsive or non-impulsive (for reversed scored items) behaviors and preferences .
Hamilton Depression Rating Scale (HDRS)	6 weeks	HDRS is a 21 item scale that evaluates the severity of depressive symptoms in patients.

Trial Locations

Locations (1)

Autonomous University of Queretaro; 🇲🇽 Querétaro City, Querétaro, Mexico